Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

a attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. Cinryze is for intravenous use only.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration. 

The most common adverse reactions in clinical trials associated with Cinryze were rash, headache, nausea, erythema, phlebitis and local reactions at the injection site.  Adverse events of sinusitis and upper respiratory infection also were observed in clinical trials.  No drug-related serious adverse events (SAEs) were reported in clinical trials.

Please visit http://www.viropharma.com/products/cinryze.aspx for the full U.S. Prescribing Information; the prescribing information for other countries can be found at www.viropharma.com

About Enhanze™ Technology

Enhanze™ technology is a proprietary drug delivery platform using Halozyme's first approved enzyme, recombinant human hyaluronidase or rHuPH20. When formulated with other injectable drugs, Enhanze technology can facilitate the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... OTTAWA , Dec. 24, 2014 /CNW/ - ... Superburn" is being recalled after Health Canada tests confirmed ... serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire ... is recalling the product from retail stores across ... body building purposes, including for weight loss and increased ...
(Date:12/24/2014)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... unaudited preliminary financial results for the first quarter ... 2015 Ended September 30, 2014 Financial Highlights: ... million in 1Q14 with gross margins improved to ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... Uroplasty, Inc. (NASDAQ: UPI ) announced today ... of fiscal 2012 ended June 30, 2011, at the market ... a conference call to discuss these results on Thursday, July ... Time). David Kaysen, President and Chief Executive Officer, and Medi ...
... 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... 1 clinical study for ISIS-PTP1BRx, an antisense drug for ... phosphatase-1B, PTP-1B.  ISIS-PTP1BRx is designed to increase the body,s ... glucose control for patients with type 2 diabetes.  Because ...
Cached Medicine Technology:Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011 2Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes 2Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes 3Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes 4
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... be one of the hottest styles in the next few ... company releases 26 A-line sweetheart evening dresses, and announces the ... “We are trying our best to help a lady to ... with affordable prices, we provide discounted delivery costs to our ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2
... controlled, multi-center trial has found that cardiac resynchronization ... during exercise testing, the trial,s primary endpoint, in ... problems that disrupt the heart,s normal rhythm and ... EKG. , The Resynchronization Therapy in Narrow QRS ...
... 6 ,PharmAthene, Inc. (Amex: PIP ), a ... threats, and Medarex, Inc.,(Nasdaq: MEDX ), a ... 2008 Department of Defense (DoD) appropriations bill includes ... basis to support,ongoing development of Valortim(TM), a fully ...
... Neurotech Pharmaceuticals, Inc.,a biotechnology company focused on ... diseases, announced today the completion,of enrollment of ... evaluating,NT-501, the Company,s lead product, for the ... (RP) and the dry form of age-related,macular ...
... ROCKVILLE, Md., Nov. 6 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,reported ... September 30,2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) ... approximately $3,520,000,versus $3,023,000 for the comparable period a ...
... ON, Nov. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. ... announced that Cameron Groome, Executive,Vice-President, Corporate & Strategic ... Annual Global Healthcare Conference in New York City,tomorrow. ... Time) in the Holmes,II Room of the New ...
... WEBCAST TO FOLLOW, BIRMINGHAM, Ala., Nov. 6 ... its third quarter,2007 financial results will be released on ... will host a conference call and live,webcast. The call ... Chief,Executive Officer, and Stuart Grant, Senior Vice President and ...
Cached Medicine News:Health News:Study puts brakes on extending indications for cardiac resynchronization therapy 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 3Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 4Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 5Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 6Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 7Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 2Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 2Health News:EntreMed Reports Third Quarter 2007 Financial Results 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 4Health News:EntreMed Reports Third Quarter 2007 Financial Results 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 2Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 3Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 4
... Immunoassay (EIA) IgG & IgM Test System is ... presumptive detection of human IgG & IgM antibodies ... system should be used to test serum from ... with B. burgdorferi. All positive and equivocal specimens ...
... TheraTears in a bottle becomes preservative-free ... turns into oxygen and water on ... eyes with mild to moderate dryness ... maintenance treatment. Now you can have ...
... sutures are prepared by coating the ... caprolactone/glycolide copolymer and calcium stearoyl lactylate. ... increase visibility and are also available ... established by the United States Pharmacopeia ...
... QualiCode™ B. burgdorferi IgG/IgM Western Blot Kits ... detection of antibodies to Borrelia burgdorferi. Proteins ... disruption. Purified B. burgdorferi antigens are fractionated ... a polyacrylamide slab gel in the presence ...
Medicine Products: